研究：GLP-1类减重糖尿病药物与罕见视力丧失风险小幅上升相关
据 Science Daily 报道，研究人员发现，GLP-1 类减重与糖尿病药物与一种罕见、可导致突发且可能永久性视力丧失的疾病风险小幅上升相关。相关研究结果本周经科学媒体汇总发布，引发医学界对这类广泛使用药物眼部安全性的进一步讨论。
GLP-1 类药物包括多款在美国广泛用于2型糖尿病与体重管理的处方药。报道指出，该关联为观察性研究结果，绝对风险仍低；研究与报道均未建议患者自行停药，用药调整应咨询医生。
信息来源：Science Daily（经 The Morning Brief 医疗汇总）
Study Links GLP-1 Weight-Loss and Diabetes Drugs to Slightly Higher Risk of Rare Vision Loss
Researchers have linked GLP-1 weight-loss and diabetes drugs to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss, Science Daily reported. The findings, summarized by science outlets this week, have renewed discussion of the eye safety of the widely used drug class.
GLP-1 drugs include several prescription medicines widely used in the United States for type 2 diabetes and weight management. The reported association comes from observational research and the absolute risk remains low; neither the study coverage nor clinicians advise patients to stop medication on their own — changes should be discussed with a doctor.
(Source: Science Daily)
发布：GSM·美国（发布链接）
图片来源：维基共享资源 · CC BY-SA 3.0 · 作者：Black Stripe
GSM Global · 本篇英文版 English edition of this story
